Service GLP-1 Medication Platform Offering Affordable Access to Semaglutide, Tirzepatide, and Phentermine with 24/7 Coaching, ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

College of Charleston's Kindred Hurtado examines one woman's weight-loss journey with the assistance of semaglutides.

From ‘Ozempic face’ to ‘Ozempic fingers’ and even ‘Wegovy butt,’ the potential side effects of weight loss medications have ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...